Urology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Michels J et al. – The combination of ABT–751 and docetaxel is safe and active in CRPC. Based on the cumulative safety analysis, the recommended phase II dose of ABT–751 is 200 mg daily with docetaxel 60 mg/m2 for this patient population.

Today in Oncology...keeping you current

Urothelial carcinoma transmission via kidney transplantation
Nephrology Dialysis Transplantation, 12/15/09

Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer
International Journal of Clinical Oncology, 12/15/09

Prostatic Ductal Adenocarcinoma: A Mini Review
Medical Principles and Practice, 12/15/09

Today in Prostate...keeping you current

Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer
International Journal of Clinical Oncology, 12/15/09

Prostatic Ductal Adenocarcinoma: A Mini Review
Medical Principles and Practice, 12/15/09

Prostate-Specific Antigen, Prostate Cancer, and Disorders of Hemostasis
Seminars in Thrombosis and Hemostasis, 12/14/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address